Andrew's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD. 2ND FLOOR, BEVERLY HILLS, CA, 90211.
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over 949,404,468$ worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth 18,843,106$ . The most active insiders traders include Sinai Medical Center Cedars、John Edward A.Edward St. Jo...、Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of 494,068$. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth 47,260$.
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include: